Projects per year
Personal profile
Personal profile
Dr. Yong Lu joined Houston Methodist Academic Institute in November 2021. He is an awardee of the 2021 Cancer Prevention & Research Institute of Texas Rising Stars program that recruits early-stage investigators who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.
Prior to joining Houston Methodist, he was a co-leader of Wake Forest Baptist Comprehensive Cancer Center for Signaling and Biotechnology (SBT) program. During 2019-2021, he was a member of NCI’s cell-based immunotherapy network to: (A) provide NCI with advice on the research gaps in cancer adoptive cell therapy; (B) advise the NCI on future directions of cancer adoptive cell therapy. Dr. Lu’s work focuses on translational T cell-based adoptive cell immunotherapy, targeting lung cancer, pancreatic cancer, and other cancers.
Since 2020, Dr. Lu has been awarded, as the PI, 4 R01s from NCI, 1 ACS research scholar grant, 3 cancer foundation grants, and numerous intramural and industry grants. In addition to the CPRIT Rising Star award, Dr. Lu was the winner of New Drug Development Global Campaign in 2019 held by Daiichi Sankyo Co., Ltd.
Recent representative corresponding-authored publications include: Briefings in Bioinformatics 2022 (PMID: 35037026), Cancer Cell 2022 (PMID: 34678150); Nature Biomedical Engineering 2021 (PMID: 34725506); Nature Comm 2019 (PMID: 30914642); Cancer Cell 2018 (PMID: 29894691); Nature Comm 2016 (PMID: 27492902).
Research interests
- Research concerns why adoptive cell therapies, the type of immunotherapy in which tumor-specific T cells (e.g. CAR-T cells) are given to a patient to help the body fight cancer, aren't effective against solid tumors like they are against leukemias and lymphomas.
- Overcome resistance of CAR-T cell therapy in multiple myeloma.
- The new tumor-specific Th9 cell-paradigm to eradicate advanced human tumors.
External positions
Associate Professor of Immunology in Medicine, Weill Cornell Medical College
May 1 2023 → …
Research Area Keywords
- Cancer
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 7 Active
-
Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy
5/1/24 → 4/30/29
Project: Federal Funding Agencies
-
Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors
4/1/23 → 3/31/28
Project: Federal Funding Agencies
-
Eradication of Escaped Variant Tumor Cells for Cancer Immunotherapy
9/15/22 → 8/31/26
Project: Federal Funding Agencies
-
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication
3/1/22 → 2/28/26
Project: Federal Funding Agencies
-
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy
2/1/22 → 5/31/25
Project: Federal Funding Agencies
-
Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy
Xue, G., Li, X., Kalim, M., Fang, J., Jiang, Z., Zheng, N., Wang, Z., Li, X., Abdelrahim, M., He, Z., Nikiforov, M., Jin, G. & Lu, Y., May 13 2024, In: Cancer Cell. 42, 5, p. 780-796.e6Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Erratum: Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors (Cancer Cell (2018) 33(6) (1048–1060.e7), (S1535610818302186), (10.1016/j.ccell.2018.05.004))
Lu, Y., Wang, Q., Xue, G., Bi, E., Ma, X., Wang, A., Qian, J., Dong, C. & Yi, Q., Jul 8 2024, In: Cancer Cell. 42, 7, p. 1313-1314 2 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Distinct inflammatory Th17 subsets emerge in autoimmunity and infection
Bouch, R. J., Zhang, J., Miller, B. C., Robbins, C. J., Mosher, T. H., Li, W., Krupenko, S. A., Nagpal, R., Zhao, J., Bloomfeld, R. S., Lu, Y., Nikiforov, M. A., Song, Q. & He, Z., Oct 2 2023, In: The Journal of experimental medicine. 220, 10, e20221911.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Mai, S., Hodges, A., Chen, H. M., Zhang, J., Wang, Y. L., Liu, Y., Nakatsu, F., Wang, X., Fang, J., Xu, Y., Davidov, V., Kang, K., Pingali, S. R., Ganguly, S., Suzuki, M., Konopleva, M., Prinzing, B., Zu, Y., Gottschalk, S., Lu, Y., & 2 others , Dec 15 2023, In: Cancer research. 83, 24, p. 4047-4062 16 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Mendelian randomization analysis revealed potential metabolic causal factors for breast cancer
Zhou, M., Henricks, M., Loch, V., Zhang, G., Lu, Y. & Li, X., Dec 2023, In: Scientific Reports. 13, 1, p. 14290 14290.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations
Prizes
-
2023 Distinguished Reserch Award for gene and cell therapy
Lu, Yong (Recipient), 2023
Prize: National/international honor
-
Excellence in Peer-Reviewed Publications
Lu, Yong (Recipient), Jan 2023
Prize: National/international honor